黄蔚 Wei Huang

2005年在中国科学院上海药物研究所获得有机化学博士学位。2005-2006年在美国犹他大学从事博士后研究，2006-2010年在美国马里兰大学任研究助理，2010-2012年在美国马里兰大学任助理教授。2012年受聘于上海药物研究所，担任课题组长。长期从事糖类药物研究，在糖化学和糖生物学交叉领域，发展新的糖类药物设计技术，在糖基化优化的单克隆抗体药物、基于糖链定点的抗体药物偶联物（ADC）药物、抗耐药菌的糖肽抗生素、糖苷类小分子抗肿瘤药物、靶向受体糖基化干预策略等项目上，取得了积极的成果，相应的药物候选分子在进行系统的临床前评价。研究成果在Nat. Chem. Biol., Nat. Protoco., Angew. Chem. Int. Ed., J. Am. Chem. Soc., J. Med. Chem.等专业期刊发表文章70余篇，近5年引用数大于2500次，H-index为28。

Received Ph.D. in organic chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2005. Conducted postdoctoral research at the University of Utah from 2005-2006, served as research assistant at the University of Maryland from 2006-2010, and as assistant professor at the University of Maryland from 2010-2012. Joined Shanghai Institute of Materia Medica as principal investigator in 2012. Has long been engaged in carbohydrate drug research. In the interdisciplinary field of glycochemistry and glycobiology, he has developed new carbohydrate drug design technologies and achieved positive results in projects including glycosylation-optimized monoclonal antibody drugs, glycan site-specific antibody-drug conjugates (ADC), glycopeptide antibiotics against drug-resistant bacteria, small molecule glycoside anticancer drugs, and receptor glycosylation-targeted intervention strategies. Corresponding drug candidates are undergoing systematic preclinical evaluation. Research results have been published in over 70 articles in professional journals such as Nat. Chem. Biol., Nat. Protoco., Angew. Chem. Int. Ed., J. Am. Chem. Soc., J. Med. Chem., with over 2500 citations in the past 5 years and an H-index of 28.

1. Shi, W.#; Tang, F.#; et al, Yang, W.*; Huang, W.* (2020) “Manipulating the click reactivity of dibenzoazacyclooctynes: from azide click component to caged acylation reagent by silver catalysis.” Angew. Chem. Int. Ed. 59(45), 19940-19944. doi.org/10.1002/anie.202009408.